Researchers used a cross-vaccination strategy in the trial, which involved 33 healthy adult volunteers between the ages of 21 and 45.
Vaccine Development
A novel vaccine candidate that offers protection against Lassa fever has been developed by researchers from Thomas Jefferson University and the University of Maryland Baltimore, in partnership with the Geneva Foundation and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). In preclinical animal models, the study, which […]
